AtaiBeckley (ATAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Voting matters and shareholder proposals
Election of three Class I directors: Sabrina Martucci Johnson, Amir Kalali, M.D., and Andrea Heslin Smiley, with board recommending a vote in favor.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, recommended by the board.
Other business may be addressed as properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board is presenting three nominees for Class I director positions for election at the annual meeting.
Audit committee and external auditor matters
Proposal to ratify Deloitte & Touche LLP as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AtaiBeckley
- Advancing late-stage psychedelics for mental health, with key phase III and II-B trials underway.ATAI
7th Annual HCW Neuro Perspectives Hybrid Conference15 Jun 2026 - Directors and auditor ratified as company advances next-gen mental health therapies.ATAI
AGM 20264 Jun 2026 - BPL-003 enters phase III for depression, with top-line data expected in early 2029.ATAI
Jefferies Global Healthcare Conference 20263 Jun 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance in place.ATAI
Proxy filing18 May 2026 - Q1 2026 net loss rose to $29.8M on higher R&D and G&A costs; cash runway extends into 2029.ATAI
Q1 202618 May 2026 - Phase III trials advance BPL-003 in TRD and EMP-01 shows rapid efficacy in social anxiety disorder.ATAI
TD Cowen 46th Annual Health Care Conference18 May 2026 - BPL-003’s rapid, durable efficacy and convenience drive its advancement to Phase 3 in TRD.ATAI
Investor Day 20268 May 2026 - Accelerated regulatory pathways and robust clinical data are driving psychedelics toward market launch.ATAI
Needham Virtual Psychedelics Forum28 Apr 2026 - BPL-003 advances to phase III for TRD, aiming for rapid, durable relief and Q1 2029 results.ATAI
25th Annual Needham Virtual Healthcare Conference16 Apr 2026